Roche to Cochrane critics: Let's compromise on Tamiflu data

Roche ($RHHBY) is making a "fair and transparent" offer to critics at the Cochrane Collaboration: Let's set up an advisory board to review all the data on Tamiflu. As Reuters reports, the proposal is Roche's latest response to calls for open access to data on its flu-fighting drug. That data has become the subject of a heated public debate, as Cochrane researchers took to the pages of the British Medical Journal. Some have even called for a Tamiflu boycott until Roche opens the books. Story

THE LIBRARY: WEBINAR

In this webinar, Dr. Frank Smith will explore advances in precision medicine and how it is affecting clinical research. As a pediatric hematologist/oncologist, he will use his extensive clinical and research background as a backdrop for the discussion. Register Now!